Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02187783
Title LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications

Advanced Solid Tumor

hematologic cancer

Therapies

Ribociclib

Age Groups: adult
Covered Countries USA

Additional content available in CKB BOOST